[B01AD01, streptokinase, The risk or severity of bleeding can be increased when Streptokinase is combined with Mitoxantrone.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mitoxantrone.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Mitoxantrone.]
[L04AA27, fingolimod, Mitoxantrone may increase the immunosuppressive activities of Fingolimod.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Mitoxantrone.]
[M04AB02, sulfinpyrazone, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Mitoxantrone.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Mitoxantrone.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be increased when combined with Mitoxantrone.]
[L01CB02, teniposide, The risk or severity of adverse effects can be increased when Teniposide is combined with Mitoxantrone.]
[B01AE07, dabigatran etexilate, The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Mitoxantrone.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Mitoxantrone is combined with Tetracaine.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Mitoxantrone.]
[R03DA04, theophylline, The metabolism of Theophylline can be increased when combined with Mitoxantrone.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Eribulin.]
[L01AC01, thiotepa, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Thiotepa.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Mitoxantrone.]
[B01AC05, ticlopidine, The risk or severity of bleeding can be increased when Ticlopidine is combined with Mitoxantrone.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Mitoxantrone.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Mitoxantrone.]
[S01BA05, triamcinolone, The risk or severity of adverse effects can be increased when Triamcinolone is combined with Mitoxantrone.]
[C03AA06, trichlormethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Mitoxantrone.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Mitoxantrone.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Fluclorolone.]
[R03BA07, mometasone, The risk or severity of adverse effects can be increased when Mometasone is combined with Mitoxantrone.]
[N03AC02, trimethadione, The metabolism of Trimethadione can be increased when combined with Mitoxantrone.]
[R03DX07, roflumilast, Roflumilast may increase the immunosuppressive activities of Mitoxantrone.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Belimumab.]
[L01EX04, vandetanib, Vandetanib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[J05AG05, rilpivirine, Rilpivirine may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[B01AD04, urokinase, The risk or severity of bleeding can be increased when Urokinase is combined with Mitoxantrone.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Belatacept.]
[B01AF01, rivaroxaban, The risk or severity of bleeding can be increased when Rivaroxaban is combined with Mitoxantrone.]
[B01AC24, ticagrelor, The risk or severity of bleeding can be increased when Ticagrelor is combined with Mitoxantrone.]
[L01CA01, vinblastine, The risk or severity of adverse effects can be increased when Vinblastine is combined with Mitoxantrone.]
[L01CA02, vincristine, The risk or severity of adverse effects can be increased when Vincristine is combined with Mitoxantrone.]
[L01CA03, vindesine, The risk or severity of adverse effects can be increased when Vindesine is combined with Mitoxantrone.]
[B03BA01, vitamin B12, The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Mitoxantrone.]
[B01AA03, warfarin, The risk or severity of bleeding can be increased when Warfarin is combined with Mitoxantrone.]
[S01AA13, fusidic acid, Fusidic acid may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Mitoxantrone.]
[L01EC01, vemurafenib, Vemurafenib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[L01FX05, brentuximab vedotin, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Brentuximab vedotin.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Mitoxantrone.]
[A02BC04, rabeprazole, Rabeprazole may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mitoxantrone.]
[N02BA01, aspirin, The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Mitoxantrone.]
[L01EJ01, ruxolitinib, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Ruxolitinib.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mitoxantrone.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Mitoxantrone.]
[L01XJ01, vismodegib, Vismodegib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[H02AB11, prednylidene, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Prednylidene.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Mitoxantrone.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Azacitidine is combined with Mitoxantrone.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Azathioprine is combined with Mitoxantrone.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Mitoxantrone.]
[G04BE10, avanafil, Avanafil may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Mitoxantrone.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mitoxantrone.]
[L01FD02, pertuzumab, The risk or severity of cardiotoxicity can be increased when Mitoxantrone is combined with Pertuzumab.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Carfilzomib.]
[V03AX03, cobicistat, Cobicistat may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[L01EA04, bosutinib, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Bosutinib.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Teriflunomide.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Defibrotide is combined with Mitoxantrone.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Abetimus.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Aldosterone.]
[L01EX05, regorafenib, Regorafenib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[C01AA01, acetyldigitoxin, Acetyldigitoxin may decrease the cardiotoxic activities of Mitoxantrone.]
[J05AE04, nelfinavir, Nelfinavir may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Bendamustine.]
[L04AA29, tofacitinib, Mitoxantrone may increase the immunosuppressive activities of Tofacitinib.]
[L01EA05, ponatinib, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Ponatinib.]
[B01AF02, apixaban, The risk or severity of bleeding can be increased when Apixaban is combined with Mitoxantrone.]
[C03AA01, bendroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Mitoxantrone.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Pomalidomide.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Dimethyl fumarate.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Mitoxantrone is combined with Benzocaine.]
[L04AA18, everolimus, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Everolimus.]
[L01EC02, dabrafenib, Dabrafenib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Mitoxantrone is combined with Benzyl alcohol.]
[L01EB03, afatinib, Afatinib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[L03AA14, lipegfilgrastim, Mitoxantrone may increase the myelosuppressive activities of Lipegfilgrastim.]
[L01EL01, ibrutinib, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Ibrutinib.]
[J05AP05, simeprevir, Simeprevir may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[L04AA32, apremilast, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Apremilast.]
[S03BA03, betamethasone, The risk or severity of adverse effects can be increased when Betamethasone is combined with Mitoxantrone.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Argatroban is combined with Mitoxantrone.]
[L04AC11, siltuximab, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Siltuximab.]
[B01AC26, vorapaxar, The risk or severity of bleeding can be increased when Vorapaxar is combined with Mitoxantrone.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Vedolizumab.]
[B01AA07, acenocoumarol, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Mitoxantrone.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Belinostat.]
[L01EM01, idelalisib, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Idelalisib.]
[N07XX08, tafamidis, The serum concentration of Mitoxantrone can be increased when it is combined with Tafamidis.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Peginterferon beta-1a.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Decitabine.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Pirfenidone.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Blinatumomab.]
[J05AP09, dasabuvir, Dasabuvir may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[L01XK01, olaparib, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Olaparib.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Dicoumarol is combined with Mitoxantrone.]
[B01AF03, edoxaban, The risk or severity of bleeding can be increased when Edoxaban is combined with Mitoxantrone.]
[L04AC10, secukinumab, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Secukinumab.]
[L01EF01, palbociclib, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Palbociclib.]
[L01XH03, panobinostat, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Panobinostat.]
[J05AP07, daclatasvir, Daclatasvir may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[N02BE01, acetaminophen, The metabolism of Acetaminophen can be increased when combined with Mitoxantrone.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Mitoxantrone.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Tioclomarol is combined with Mitoxantrone.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Cangrelor is combined with Mitoxantrone.]
[A04AD14, rolapitant, Rolapitant may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[A02BC03, lansoprazole, Lansoprazole may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be increased when combined with Mitoxantrone.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Mepolizumab.]
[J02AC05, isavuconazole, Isavuconazole may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[L01EB04, osimertinib, Osimertinib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[L01ED03, alectinib, Alectinib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[J05AP10, elbasvir, Elbasvir may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[J05AP11, grazoprevir, Grazoprevir may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Ixekizumab.]
[L01XX52, venetoclax, Venetoclax may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Mitoxantrone is combined with Bupivacaine.]
[N07BC01, buprenorphine, Buprenorphine may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[L01AB01, busulfan, The risk or severity of adverse effects can be increased when Busulfan is combined with Mitoxantrone.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Mitoxantrone.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[L01XK03, rucaparib, Rucaparib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Brodalumab.]
[L04AA36, ocrelizumab, Ocrelizumab may increase the immunosuppressive activities of Mitoxantrone.]
[N06BC01, caffeine, Caffeine may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Mitoxantrone is combined with Oxybuprocaine.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Mitoxantrone.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Mitoxantrone.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Infliximab is combined with Mitoxantrone.]
[L01ED04, brigatinib, Brigatinib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[N04BD03, safinamide, Safinamide may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Sarilumab.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Betrixaban is combined with Mitoxantrone.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Guselkumab.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Capecitabine is combined with Mitoxantrone.]
[L01XX59, enasidenib, Enasidenib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Vorinostat.]
[L01EF03, abemaciclib, Abemaciclib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Mitoxantrone.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Mitoxantrone.]
[V03AF08, palifermin, The therapeutic efficacy of Palifermin can be decreased when used in combination with Mitoxantrone.]
[R03BA02, budesonide, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Budesonide.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Mitoxantrone.]
[J05AX18, letermovir, Letermovir may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[C01AA02, acetyldigoxins, Acetyldigoxin may decrease the cardiotoxic activities of Mitoxantrone.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Mitoxantrone is combined with Capsaicin.]
[L02BB05, apalutamide, Apalutamide may increase the excretion rate of Mitoxantrone which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be increased when Carbamazepine is combined with Mitoxantrone.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Mitoxantrone.]
[C07AG02, carvedilol, The metabolism of Carvedilol can be increased when combined with Mitoxantrone.]
[B02BX09, fostamatinib, Fostamatinib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[N03AX24, cannabidiol, Cannabidiol may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[B02BX08, avatrombopag, Avatrombopag may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Baricitinib.]
[N03AX17, stiripentol, The excretion of Mitoxantrone can be decreased when combined with Stiripentol.]
[L01EB07, dacomitinib, Dacomitinib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Mitoxantrone is combined with Chloroprocaine.]
[L04AA39, emapalumab, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Mitoxantrone.]
[L01EX13, gilteritinib, Gilteritinib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[L01XJ03, glasdegib, Glasdegib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Ravulizumab.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Mitoxantrone.]
[B01AC23, cilostazol, The risk or severity of bleeding can be increased when Cilostazol is combined with Mitoxantrone.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Siponimod.]
[H02AB14, cloprednol, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Cloprednol.]
[L04AB01, etanercept, The risk or severity of adverse effects can be increased when Etanercept is combined with Mitoxantrone.]
[H02AB17, cortivazol, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Risankizumab.]
[L02BB06, darolutamide, Darolutamide may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Upadacitinib.]
[L01EJ02, fedratinib, Fedratinib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[N04CX01, istradefylline, Istradefylline may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[C03AA09, cyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Mitoxantrone.]
[H02AB13, deflazacort, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Deflazacort.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Mitoxantrone.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Trastuzumab emtansine.]
[N02CC08, lasmiditan, The serum concentration of Mitoxantrone can be increased when it is combined with Lasmiditan.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Diroximel fumarate.]
[N03AX25, cenobamate, The metabolism of Cenobamate can be increased when combined with Mitoxantrone.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Teprotumumab.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Ozanimod.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be increased when combined with Mitoxantrone.]
[L01XF03, bexarotene, The risk or severity of adverse effects can be increased when Bexarotene is combined with Mitoxantrone.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Mitoxantrone.]
[S03AA08, chloramphenicol, The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Mitoxantrone.]
[L01EX17, capmatinib, The serum concentration of Mitoxantrone can be increased when it is combined with Capmatinib.]
[D07XB03, fluprednidene, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Fluprednidene.]
[L01EX19, ripretinib, Ripretinib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Mitoxantrone.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Mitoxantrone is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Mitoxantrone is combined with Dyclonine.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Stepronin.]
[J05AX29, fostemsavir, Fostemsavir may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[L04AC19, satralizumab, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Satralizumab.]
[L01EX23, pralsetinib, Pralsetinib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[C03AA04, chlorothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Mitoxantrone.]
[M03BB03, chlorzoxazone, The metabolism of Chlorzoxazone can be increased when combined with Mitoxantrone.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Fludarabine is combined with Mitoxantrone.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Voclosporin.]
[L01EX21, tepotinib, Tepotinib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[N03AX10, felbamate, The metabolism of Felbamate can be increased when combined with Mitoxantrone.]
[R03BA03, flunisolide, The risk or severity of adverse effects can be increased when Flunisolide is combined with Mitoxantrone.]
[S02BA08, fluocinolone acetonide, The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Mitoxantrone.]
[L04AA50, ponesimod, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Ponesimod.]
[S01LA08, bevacizumab, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Mitoxantrone.]
[L01EK03, tivozanib, Tivozanib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Mitoxantrone.]
[L01XX73, sotorasib, The serum concentration of Mitoxantrone can be increased when it is combined with Sotorasib.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Mitoxantrone.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Pegcetacoplan.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Belumosudil.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Anifrolumab.]
[J05AX10, maribavir, Maribavir may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Ropeginterferon alfa-2b.]
[J04BA01, clofazimine, Clofazimine may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Tenecteplase is combined with Mitoxantrone.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Mitoxantrone is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Mitoxantrone can be increased when it is combined with Pacritinib.]
[J02AC06, oteseconazole, The serum concentration of Mitoxantrone can be increased when it is combined with Oteseconazole.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Deucravacitinib.]
[N05AH02, clozapine, The risk or severity of neutropenia can be increased when Mitoxantrone is combined with Clozapine.]
[A10BK06, sotagliflozin, Sotagliflozin may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Mitoxantrone is combined with Cocaine.]
[L04AC21, bimekizumab, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Bimekizumab.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Leflunomide.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Nelarabine.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Ciclesonide.]
[B01AC10, indobufen, The risk or severity of bleeding can be increased when Indobufen is combined with Mitoxantrone.]
[C01AA06, lanatoside C, Lanatoside C may decrease the cardiotoxic activities of Mitoxantrone.]
[J02AC02, itraconazole, Itraconazole may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Bemiparin is combined with Mitoxantrone.]
[L01EA01, imatinib, The risk or severity of adverse effects can be increased when Imatinib is combined with Mitoxantrone.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Mitoxantrone.]
[H02AB15, meprednisone, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Meprednisone.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Mitoxantrone.]
[C03AA07, cyclopenthiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Mitoxantrone.]
[L01AA01, cyclophosphamide, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Mitoxantrone.]
[S01XA18, cyclosporine, The serum concentration of Mitoxantrone can be increased when it is combined with Cyclosporine.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Mitoxantrone.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Dacarbazine is combined with Mitoxantrone.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Dactinomycin is combined with Mitoxantrone.]
[L01DB02, daunorubicin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Mitoxantrone.]
[B01AX05, fondaparinux, The risk or severity of bleeding can be increased when Fondaparinux is combined with Mitoxantrone.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mitoxantrone.]
[C01AA07, deslanoside, Deslanoside may decrease the cardiotoxic activities of Mitoxantrone.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Mitoxantrone.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Mitoxantrone.]
[S03BA01, dexamethasone, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Dexamethasone.]
[L04AB04, adalimumab, The risk or severity of adverse effects can be increased when Adalimumab is combined with Mitoxantrone.]
[L01EB01, gefitinib, Gefitinib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[B01AC04, clopidogrel, The risk or severity of bleeding can be increased when Clopidogrel is combined with Mitoxantrone.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Mitoxantrone is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Mitoxantrone is combined with Cinchocaine.]
[L01DC04, ixabepilone, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Ixabepilone.]
[L01EB02, erlotinib, Erlotinib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Pirarubicin.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[D07XC04, diflucortolone, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Difluocortolone.]
[C01AA04, digitoxin, Digitoxin may decrease the cardiotoxic activities of Mitoxantrone.]
[C01AA05, digoxin, Digoxin may decrease the cardiotoxic activities of Mitoxantrone.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mitoxantrone.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Mitoxantrone.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Mitoxantrone is combined with Pramocaine.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Mitoxantrone is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Mitoxantrone is combined with Diphenhydramine.]
[B01AC07, dipyridamole, The risk or severity of bleeding can be increased when Dipyridamole is combined with Mitoxantrone.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Mitoxantrone.]
[S01XA23, sirolimus, The risk or severity of adverse effects can be increased when Sirolimus is combined with Mitoxantrone.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Natalizumab.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Mitoxantrone.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Mitoxantrone is combined with Ropivacaine.]
[L01EX01, sunitinib, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Sunitinib.]
[L01XG01, bortezomib, The risk or severity of adverse effects can be increased when Bortezomib is combined with Mitoxantrone.]
[L01DB01, doxorubicin, The risk or severity of adverse effects can be increased when Doxorubicin is combined with Mitoxantrone.]
[N01AB08, sevoflurane, The metabolism of Sevoflurane can be increased when combined with Mitoxantrone.]
[H01AA01, corticotropin, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Corticotropin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Temozolomide is combined with Mitoxantrone.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Triflusal is combined with Mitoxantrone.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Trilostane is combined with Mitoxantrone.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Trofosfamide.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Troxerutin is combined with Mitoxantrone.]
[N01AB04, enflurane, The metabolism of Enflurane can be increased when combined with Mitoxantrone.]
[L01CA04, vinorelbine, The risk or severity of adverse effects can be increased when Vinorelbine is combined with Mitoxantrone.]
[N06AX16, venlafaxine, Venlafaxine may increase the excretion rate of Mitoxantrone which could result in a lower serum level and potentially a reduction in efficacy.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Mitoxantrone.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Anistreplase is combined with Mitoxantrone.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Mitoxantrone.]
[B01AC11, iloprost, The risk or severity of bleeding can be increased when Iloprost is combined with Mitoxantrone.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[G03CA03, estradiol, Estradiol may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Estramustine is combined with Mitoxantrone.]
[R03BA05, fluticasone, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Fluticasone.]
[N03AD01, ethosuximide, The metabolism of Ethosuximide can be increased when combined with Mitoxantrone.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Mitoxantrone is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Mitoxantrone is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Mitoxantrone is combined with Etidocaine.]
[L01CB01, etoposide, The risk or severity of adverse effects can be increased when Etoposide is combined with Mitoxantrone.]
[L04AD02, tacrolimus, Tacrolimus may increase the immunosuppressive activities of Mitoxantrone.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Mitoxantrone.]
[C10AA03, pravastatin, Pravastatin may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[B05AA05, dextran, The risk or severity of bleeding can be increased when Dextran is combined with Mitoxantrone.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mitoxantrone.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Fibrinolysin is combined with Mitoxantrone.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Mitoxantrone.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Mitoxantrone.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Flucytosine is combined with Mitoxantrone.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Mitoxantrone.]
[D07AC08, fluocinonide, The risk or severity of adverse effects can be increased when Fluocinonide is combined with Mitoxantrone.]
[H02AB03, fluocortolone, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Fluocortolone.]
[V03AZ01, ethanol, The metabolism of Ethanol can be increased when combined with Mitoxantrone.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Mitoxantrone.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Mitoxantrone.]
[L01BC02, fluorouracil, The risk or severity of adverse effects can be increased when Fluorouracil is combined with Mitoxantrone.]
[N05AF01, flupenthixol, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Mitoxantrone.]
[L01EA02, dasatinib, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Dasatinib.]
[L01EX02, sorafenib, The risk or severity of adverse effects can be increased when Sorafenib is combined with Mitoxantrone.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Fluindione is combined with Mitoxantrone.]
[N01AB01, halothane, The metabolism of Halothane can be increased when combined with Mitoxantrone.]
[L01CE02, irinotecan, The risk or severity of adverse effects can be increased when Irinotecan is combined with Mitoxantrone.]
[M04AA01, allopurinol, The risk or severity of adverse effects can be increased when Allopurinol is combined with Mitoxantrone.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Heparin is combined with Mitoxantrone.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Mitoxantrone.]
[C08CA10, nilvadipine, The metabolism of Nilvadipine can be increased when combined with Mitoxantrone.]
[M02AA26, nimesulide, The risk or severity of bleeding can be increased when Nimesulide is combined with Mitoxantrone.]
[C03AA03, hydrochlorothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Mitoxantrone.]
[D07AB02, hydrocortisone butyrate, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Hydrocortisone butyrate.]
[C03AA02, hydroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Mitoxantrone.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Hydroxychloroquine.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Mitoxantrone.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Sodium citrate is combined with Mitoxantrone.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Idarubicin is combined with Mitoxantrone.]
[L01AA06, ifosfamide, The risk or severity of adverse effects can be increased when Ifosfamide is combined with Mitoxantrone.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Paclitaxel.]
[L01CD03, paclitaxel poliglumex, The risk or severity of cardiotoxicity can be increased when Mitoxantrone is combined with Paclitaxel poliglumex.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Tixocortol.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Topotecan is combined with Mitoxantrone.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Mitoxantrone.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Mitoxantrone.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mitoxantrone.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Eculizumab.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Mitoxantrone is combined with Articaine.]
[L01XX35, anagrelide, The risk or severity of bleeding can be increased when Anagrelide is combined with Mitoxantrone.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mitoxantrone.]
[N01AB06, isoflurane, The metabolism of Isoflurane can be increased when combined with Mitoxantrone.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Bivalirudin is combined with Mitoxantrone.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Tocilizumab.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Ketanserin is combined with Mitoxantrone.]
[B01AC22, prasugrel, The risk or severity of bleeding can be increased when Prasugrel is combined with Mitoxantrone.]
[L04AA24, abatacept, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Abatacept.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Mitoxantrone.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Mitoxantrone is combined with Lidocaine.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Lomustine.]
[L01EG01, temsirolimus, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Temsirolimus.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Pralatrexate.]
[L01EA03, nilotinib, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Nilotinib.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Mitoxantrone.]
[C01AA08, medigoxin, Metildigoxin may decrease the cardiotoxic activities of Mitoxantrone.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Nadroparin is combined with Mitoxantrone.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Enoxaparin is combined with Mitoxantrone.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Dalteparin is combined with Mitoxantrone.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Melphalan is combined with Mitoxantrone.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Mitoxantrone is combined with Mepivacaine.]
[H03BB02, methimazole, The risk or severity of adverse effects can be increased when Methimazole is combined with Mitoxantrone.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Pemetrexed is combined with Mitoxantrone.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Methotrexate is combined with Mitoxantrone.]
[N02BG09, methoxyflurane, The metabolism of Methoxyflurane can be increased when combined with Mitoxantrone.]
[C03AA08, methyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Mitoxantrone.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be increased when combined with Mitoxantrone.]
[H02AB04, methylprednisolone, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Mitoxantrone.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Parnaparin is combined with Mitoxantrone.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Tinzaparin is combined with Mitoxantrone.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Antilymphocyte immunoglobulin (horse).]
[R03BA09, fluticasone furoate, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Fluticasone furoate.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Mitoxantrone.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Certolizumab pegol.]
[B02BX05, eltrombopag, Eltrombopag may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Ofatumumab.]
[L01EX03, pazopanib, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Pazopanib.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Mitoxantrone.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mitoxantrone.]
[L04AC03, anakinra, The risk or severity of adverse effects can be increased when Anakinra is combined with Mitoxantrone.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Mitoxantrone.]
[L01CD02, docetaxel, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Docetaxel.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Tirofiban is combined with Mitoxantrone.]
[C09CA07, telmisartan, Telmisartan may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[M04AA03, febuxostat, The excretion of Mitoxantrone can be decreased when combined with Febuxostat.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Mitoxantrone.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Mitoxantrone.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Reviparin is combined with Mitoxantrone.]
[L04AC04, rilonacept, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Rilonacept.]
[A02BC01, omeprazole, Omeprazole may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Reteplase is combined with Mitoxantrone.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Ancrod is combined with Mitoxantrone.]
[C01AC01, ouabain, Ouabain may decrease the cardiotoxic activities of Mitoxantrone.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Danaparoid is combined with Mitoxantrone.]
[H02AB05, paramethasone, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Paramethasone.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Penicillamine is combined with Mitoxantrone.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Mitoxantrone.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Mitoxantrone.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Mitoxantrone.]
[C04AD03, pentoxifylline, The risk or severity of bleeding can be increased when Pentoxifylline is combined with Mitoxantrone.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Mitoxantrone.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Phenindione is combined with Mitoxantrone.]
[N03AA02, phenobarbital, The metabolism of Phenobarbital can be increased when combined with Mitoxantrone.]
[B01AA04, phenprocoumon, The risk or severity of bleeding can be increased when Phenprocoumon is combined with Mitoxantrone.]
[N03AB02, phenytoin, The metabolism of Phenytoin can be increased when combined with Mitoxantrone.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Golimumab.]
[J05AE01, saquinavir, Saquinavir may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Abciximab is combined with Mitoxantrone.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Alteplase is combined with Mitoxantrone.]
[A10BG02, rosiglitazone, The metabolism of Rosiglitazone can be increased when combined with Mitoxantrone.]
[L02BG03, anastrozole, The risk or severity of cardiotoxicity can be increased when Mitoxantrone is combined with Anastrozole.]
[L04AC08, canakinumab, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Canakinumab.]
[C03AA05, polythiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Mitoxantrone.]
[J05AE03, ritonavir, Ritonavir may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[S03BA02, prednisolone, The risk or severity of adverse effects can be increased when Prednisolone is combined with Mitoxantrone.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Mitoxantrone.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Mitoxantrone is combined with Prilocaine.]
[N03AA03, primidone, The metabolism of Primidone can be increased when combined with Mitoxantrone.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Mitoxantrone is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Mitoxantrone.]
[G03DA04, progesterone, Progesterone may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Mitoxantrone.]
[C01AB01, proscillaridin, Proscillaridin may decrease the cardiotoxic activities of Mitoxantrone.]
[B01AC09, epoprostenol, The risk or severity of bleeding can be increased when Epoprostenol is combined with Mitoxantrone.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Mitoxantrone.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Mitoxantrone.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Obinutuzumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Mitoxantrone.]
[L01CD04, cabazitaxel, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Cabazitaxel.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Mitoxantrone.]
